

**Forum for Collaborative HIV Research
HCV Drug Resistance/Cross-Resistance Advisory Group Meeting**

**Sheraton Premiere, Tysons Corner
8661 Leesburg Pike, Vienna, VA 22182**

May 18, 2007

AGENDA

7:30 - 8:30	Breakfast	
8:30 - 8:45	Welcome and Introductions	Ben Cheng
8:45 - 9:00	Goals of the HCV DRAG	Dale Kempf
9:00 - 9:30	HBV/HIV Lessons Learned	Scott Bowden & Doug Richman
9:30 - 9:45	Regulatory Perspective	Jules O'Rear
9:45 - 11:30	Can we standardize what should be sequenced for different classes of compounds or combinations of compounds? What are the merits and limitations of this approach? Issues to be discussed: 1) Sensitivity 2) Clonal versus population 3) Determination of linkage 4) Technologies for sequencing 5) Databases	Ann Kwong
11:30 - 11:45	Break	
11:45 - 1:30	Can we standardize the performance of clinical virology studies? In clinical trials/practice, when should resistance testing be done? Issues to be discussed: 1) Definition of terms 2) Sampling for resistance testing	Chip Schooley
1:30 - 2:00	Lunch	
2:00 - 3:45	Phenotypic resistance testing Issues to be discussed: 1) phenotyping technologies 2) Use of replicons versus enzymatic 3) Non genotype 1 studies	Neil Parkin
3:45 - 5:00	Moving forward/Next steps	Dale Kempf